Tenaya Therapeutics, Inc. 8-K

What Happened

• On March 11, 2026, Tenaya Therapeutics, Inc. (TNYA) announced financial results for the quarter and full year ended December 31, 2025 via an earnings press release. The company furnished the full text of that press release as Exhibit 99.1 to its Form 8-K under Item 2.02 (Results of Operations and Financial Condition).

Key Details

• Filing date: March 11, 2026 (Form 8-K).
• Reporting period: quarter and full year ended December 31, 2025.
• Press release included as Exhibit 99.1 and incorporated by reference in the 8-K.
• The company stated the furnished information is not "filed" for purposes of Section 18 of the Exchange Act and is not to be incorporated by reference in other filings except by specific reference.

Why It Matters

• This 8-K formally notifies investors that Tenaya has released its latest earnings and financial condition information for Q4 and full-year 2025; investors should review the attached press release (Exhibit 99.1) for revenue, expenses, guidance, and other metrics.
• The disclosure status note (not deemed “filed” under Section 18) limits how the press release may be used in future SEC filings, which is a common legal reservation but important for how the information can be relied upon in other filings.